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Abstract: Basal-like breast cancer has been reported to be the most aggressive and deadly carcinoma sub-type. Patients diagnosed with 
this subtype have a less than 50% five-year survival. In addition, many studies have reported that this sub-type is more prevalent in 
specific ethnic groups and is believed to be a key factor that drives certain ethnic disparities in mortality. In order to effectively study 
this sub-type and determine unique gene expression and biochemical pathways which sustain this cancer’s growth, we sought to identify 
human breast cancer cell lines that represent a model for the basal-like subtype. Here, we report our findings which indicate the African 
American cell line CRL-2335 is a true representative of basal-like breast carcinoma.
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Introduction
Breast  cancer  has  a  high  level  of  heterogeneity 
throughout the global population.1 While the disease 
as a whole is often reported to the public through 
national surveillance databases as a single disease, 
oncologists  and  researchers  agree  that  there  are 
several clinical types of breast cancer, with distinct 
etiologies  and  distribution  of  both  incidence  and 
survival  among  women.1–6  Based  on  histological 
analyses  which  measure  presence  of  Estrogen 
Receptor (ER), Progesterone Receptor (PR), human 
epidermal growth factor receptor 2 (HER2/Neu) gene 
amplification,  Epidermal  Growth  Factor  Receptor 
(EGFR) and cytokeratin 5/6 (ck 5/6), breast cancer 
is clinically grouped into five pathologically distinct 
subtypes: Luminal A, Luminal B, HER2 amplified, 
basal-like,  and  unclassified.7–9  These  subtypes 
illustrate the etiology of distinct cancer diseases that 
respond to specific treatment regimens.
There is an observed bias of incidence distribu-
tions among ethnic populations of women for each of 
these subtypes. While African American women have 
a lower incidence of breast cancer than   Caucasian 
women, they are more likely to present with tumors 
that are early onset, higher grade, and ER negative and 
therefore have a lower survival rate.10–12   Premenopausal 
African American women have a higher   prevalence of 
basal-like tumors than Caucasian women of the same 
age,12–16 while Caucasian women more often   present 
with Luminal subtypes. This same trend has been seen 
in Britain,17 and a recent study determined that triple 
negative tumors represent the majority of breast can-
cer tumors in the West   African population.12 In addi-
tion, a number of biological differences have been 
found in breast   cancers in   African American women, 
including BRCA   mutations, higher expression of cell 
cycle regulators, and   polymorphisms in cytochrome 
p450 and nucleotide excision repair genes.15
While there is recent controversy as to the dispari-
ties of these subtypes among different ancestral groups, 
all clinical data agree that the most aggressive subtype, 
which associates with the highest mortality rate, is the 
basal-like subtype.5,18,19 This particular subtype is a deriv-
ative of the Estrogen Receptor (ER) negative category 
of breast cancers, but it is   further characterized by hav-
ing no amplification of the HER2 gene, and by expres-
sion of EGFR as well as the basal epithelial marker, 
cytokeratin 5/6.2 Due to this lack of ER expression and   
HER2 overexpression there are   currently no targeted 
therapies for basal-like tumors. This lack of therapy, in 
addition  to  the  subtypes  high  proliferative  capacity8,9 
leads to poor clinical outcomes.13
As  we  investigate  the  genetic  and  epigenetic 
mechanisms that drive this basal-like cancer, we sought 
to identify cell lines that may act as an in vitro model 
for experimental screen and potential tumorigenesis 
work. A recent publication has outlined approximately 
17 cell lines and characterized them into the Luminal 
and basal subtypes.20 However, we report an additional 
basal-like cell line which is derived from a African 
American female, which will be an essential tool in 
unraveling  not  only  basal-like  carcinoma  specific 
mechanisms, but additionally genetic ancestral associa-
tions among these mechanisms related to basal-like 
breast cancer disparities.
results
CRL-2335 is confirmed ER negative
The cell line annotation report provided by ATCC 
indicates this cell line was derived from a primary, 
stage  IIB,  grade  2,  ancantholytic  squamous  cell 
carcinoma with no lymph node metastasis. The line 
was designated as negative for Her2-neu amplification 
as well as negative for the expression of ER and PR.
To  confirm  its  retained  ER  negative  status,  we 
conducted  immunofluorescence  to  measure  the 
presence or absence of ER in this cell line (Fig. 1A). 
As a positive control we determined that CRL-2315, 
which was designated to be positive for the expression 
of ER,21 has high expression of ER as indicated in our 
findings (Fig. 1A). These data indicate that CRL-2335 
is in fact an ER negative cell line. Xu et al also recently 
confirmed that CRL-2335 is negative for the expression 
of ER, PR, and Her2 by western blot analysis.22
It  should  be  noted  that  in  the  past  few  months 
ATCC  has  changed  the  molecular  status  of  CRL-
2315  from  ER  positive  to  ER  negative.  Our  data, 
however,   indicates that our line is still positive for the 
expression of ER, which demonstrates the importance 
of the periodic validation of cell lines for molecular 
status in the laboratory setting.
crL-2335 expresses Basal-Like 
Markers, eGFr and ck 5/6
In order to determine if this cell line qualifies as a 
basal-like  tumor  model,  we  conducted  additional CRL-2335 is a basal-like breast carcinoma
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immunofluorescence to measure the presence of the 
basal-like tumor markers, EGFR and ck 5/6. We found 
that CRL-2335 was positive for both markers, while 
the normal cell line CRL-1947 did not exhibit stain-
ing with either of the markers (Fig. 1B and C). The 
functional relevance of these differences is   currently 
under investigation.
To validate the positive immunostaining results for 
EGFR and ck 5/6 we conducted qPCR with CRL-2335 
and  CRL-2315.  We  normalized  average  Ct  values 
to the endogenous control, 18s, to get average dCt 
values, which are shown in Figure 2. Cell lines that 
showed  negative  protein  staining  also  showed  an 
increase in the average dCt, which correlates with 
lower expression and the lack of staining (Fig. 2). 
qPCR results suggest that EGFR is transcriptionally 
active in CRL-2315 with an average dCt of 12.04. 
However, the lack of protein staining suggests that 
the transcript is degraded and not translated into a 
functional protein. This demonstrates why in a clinical 
CRL-1947
a
b
c
d
e
f
g
h
i
j
k
l
a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
p
q
r
s
t
u
v
w
x
ck 5/6 EGFR
M
E
R
G
E
T
R
I
T
C
D
A
P
I
B
R
I
G
H
T
F
I
E
L
D
CRL-2355
ER
CRL-2135
A
CRL-1947
M
E
R
G
E
T
R
I
T
C
D
A
P
I
B
R
I
G
H
T
F
I
E
L
D
CRL-2355 CRL-2135 CRL-1947 CRL-2355 CRL-2135
B
Figure 1. Immunostaining images. A) Shows images obtained from all three cell lines when stained with an eR antibody. B) Shows images obtained from 
all three cell lines when stained with basal-like markers ck 5/6 and eGFR.hill Neves et al
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setting we rely on protein staining for diagnostics and 
not transcriptional analysis alone.
Discussion
Molecular classification has important clinical impli-
cations for breast cancer patients, as it is used to select 
treatment  options  and  for  prognostic    predictions. 
Breast cancer cell lines are readily available and are 
commonly used in breast cancer research. Since these 
cell lines are representative of a heterogeneous group 
of diseases, it is necessary to determine their sub-
classifications  in  order  to  correlate  molecular  data 
with tumor subtypes. Often we find that cell line stud-
ies have contradicting results from what is observed 
in clinical tissue studies. Part of this dilemma could 
be due to lack of subtype characterization of the cell 
lines. Even if derived from a certain tumor type, it is 
important that we characterize the molecular status of 
the in vitro lines.
Based  on  transcriptional  and  immunofluores-
cent analysis, we have characterized CRL-2335 as a 
  basal-like tumor cell line. Given its derivation from 
an   African American female, this line will be useful 
not only in breast cancer subtype studies, but also in 
genetic ancestry relevant analyses.
experimental procedures
Cell culture
CRL-2335, CRL-2315, and CRL-1947 breast carci-
noma cell lines were obtained from the American Type 
Culture Collection (ATCC). Cells were maintained at 
37 °C with 5% CO2 and were cultured in appropriate 
medium (see Table 1). For qPCR, cells were harvested 
after reaching confluence with 0.25% Trypsin-EDTA 
(Invitrogen) and washed once with 1X PBS before 
RNA isolation. For immunofluorescence, cells were 
grown on alcohol and flame sterilized selected micro 
glass coverslips (VWR) in 6 well plates (Corning) for 
48 hours prior to immunofluorescence.
RNA isolation, cDNA synthesis,  
RT-pCR and qpCR
Cell  pellets  were  resuspended  in  1  mL  TRIzol 
Reagent (Invitrogen) and RNA isolation was carried 
out  according  to  the  manufacturer’s  instructions. 
cDNA  was  then  synthesized  using  300  ng  RNA 
and qScript cDNA SuperMix (Quanta Biosciences) 
according to the manufacturer’s instructions. RT-PCR 
was  performed  using  expression  primers  for  18s 
rRNA, ck 5/6, and EGFR (Table 2) with GoTaqGreen 
Mastermix (Promega) according to the manufacturer’s 
instructions using 1 ug of cDNA. Amplification was 
resolved on a 1% agarose gel containing 0.5 ug/mL 
EtBr run at 120V for 45 minutes and single bands were 
visualized under an ultraviolet light (Supplemental 
Fig.  1).  qPCR  was  performed  using  the  same 
expression primers (Table 2) with RT2 SYBR Green/
ROX qPCR MasterMix (SABiosciences) according 
to the manufacturer’s instructions using 1 ug cDNA.
Immunofluorescence
EGFR, ck 5/6, and ER immunohistochemical analysis 
was  performed  using  purified  mouse  monoclonal 
Table 1. Cell culture conditions for breast cancer cell lines.
cell line source culture conditions
CRL-2335 ATCC RPMI-1640 (Invitrogen) with 10% FBS (Sigma) and antibiotyic/antimycotic solution at a final 
concentration of 100 I.U./mL penicillin, 100 ug/mL streptomycin, 0.25 ug/mL amphotercin 
(Cellgro)
CRL-1947 ATCC Iscove’s Modified Dulbecco’s Medium (Cellgro) with 10% FBS (Sigma) and antibiotyic/
antimycotic solution at a final concentration of 100 I.U./mL penicillin, 100 ug/mL streptomycin, 
0.25 ug/mL amphotercin (Cellgro)
CRL-2135 ATCC Same as CRL-2335
0
CRL-2315 CRL-2335
EGFR
CK5/6
Cell line
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Figure  2.  qpCR  data.  Data  is  represented  as  Average  dCt  values, 
normalized to the endogenous control 18s. A high average dCt value 
indicates a low expression value.CRL-2335 is a basal-like breast carcinoma
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  antibodies (Santa Cruz Biotechnology, CA).   Coverslips 
were rinsed twice with 1X PBS and fixed in 4% PFA/
PBS for 15 minutes. After fixation, coverslips were 
washed with 1X PBS and then blocked with PBI (1X 
PBS, 0.5% BSA (Fisher), 0.5% Igepal (Sigma)) for 
1 hour. The coverslips were then incubated overnight 
in corresponding primary antibodies (1:500) with PBI, 
washed  with  PBI,  then  incubated  with  Alexaflour 
TRITC goat anti-mouse secondary antibody (2:5000, 
Invitrogen)  in  PBI  overnight.  The  coverslips  were 
mounted in 30% glycerol after a 15-minute incuba-
tion  with  DAPI  (1:10,000,  Sigma)  in  PBI  and  two 
30-minute washes with PBI. All washes and incuba-
tions were performed on a rotator at 4 °C. Confocal 
images were taken with a Ziess Apotome using Axio-
vision software.
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Figure s1. RT-pCR. A) Results from RT-pCR using expression primers for ck 5/6. A single product is seen at 974 bp in both CRL-2315 and CRL-2335, and 
no product is seen in CRL-1947. B) Results from RT-pCR using expression primers for eGFR. A single product is seen at 169 bp in both CRL-2135 and 
CRL-2335, and no product is seen in CRL-1947. expression primers for 18s rRNA was used as a positive control, and single product was seen at 209 bp 
in all cell lines. The negative control was a RT-PCR reaction with no cDNA template to validate the specificity of the technique.
supplementary Figure